Aptose Biosciences INC. (APTOF) — SEC Filings

Overview

Aptose Biosciences INC. (APTOF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a RW filed on Mar 23, 2026: Aptose Biosciences Inc. (CIK: 0000882361) filed a Form RW on March 23, 2026, to withdraw a previously filed registration statement, File No. 333-284927. This withdrawal indicates Aptose is no longer pursuing the offering or transaction that the original registration statement covered. For investors,

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Aptose Biosciences INC. is neutral.

Filing Type Overview

Aptose Biosciences INC. (APTOF) has filed 1 RW, 43 8-K, 3 10-Q, 1 DEFA14A, 1 DEF 14A, 1 10-K with the SEC between Feb 2025 to Mar 2026.

Filings by Year

2026 · 2025

Recent Filings (50)

• Aptose Biosciences Withdraws Registration Statement 333-284927 — RW · Mar 23, 2026
  Aptose Biosciences Inc. (CIK: 0000882361) filed a Form RW on March 23, 2026, to withdraw a previously filed registration statement, File No. 333-284927. This wi
• Aptose Biosciences Files 8-K: Material Agreement & Officer Comp Changes — 8-K · Mar 23, 2026
  Aptose Biosciences Inc. filed an 8-K on March 23, 2026, reporting an "Entry into a Material Definitive Agreement" and changes in "Compensatory Arrangements of C
• Aptose Biosciences Files 8-K — 8-K · Dec 19, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on December 19, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kno
• Aptose Biosciences Files 8-K with Regulatory Updates — 8-K · Dec 8, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on December 8, 2025, reporting events as of December 6, 2025. The filing includes a Regulation FD Disclosure and Financial
• Aptose Biosciences Inc. Signs Material Definitive Agreement — 8-K · Nov 25, 2025 Risk: medium
  Aptose Biosciences Inc. entered into a material definitive agreement on November 18, 2025. The company, previously known as Lorus Therapeutics Inc. and Imutec P
• Aptose Biosciences Files 8-K — 8-K · Nov 19, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on November 19, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kno
• Aptose's Cash Dries Up, Going Concern Doubts Mount Amid Nasdaq Delisting — 10-Q · Nov 13, 2025 Risk: high
  Aptose Biosciences Inc. reported no revenue for the three and nine months ended September 30, 2025, consistent with the prior year. The company incurred a net l
• Aptose Biosciences Files 8-K on Financials — 8-K · Nov 13, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K report on November 13, 2025, to disclose information regarding its results of operations and financial condition, as well a
• Aptose Biosciences Files 8-K — 8-K · Nov 3, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on November 3, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
• Aptose Biosciences Files 8-K Report — 8-K · Oct 16, 2025 Risk: low
  On October 16, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits.
• Aptose Biosciences Files 8-K — 8-K · Sep 22, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on September 22, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly
• Aptose Biosciences Inc. Announces Board and Officer Changes — 8-K · Aug 27, 2025 Risk: medium
  Aptose Biosciences Inc. announced on August 19, 2025, changes related to its board of directors and officers. The filing details the departure of certain direct
• Aptose Biosciences Files 8-K — 8-K · Aug 25, 2025 Risk: medium
  Aptose Biosciences Inc. filed an 8-K on August 25, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial
• Aptose Biosciences Files 8-K — 8-K · Aug 22, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on August 22, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
• Aptose Biosciences Files 8-K with Regulatory Updates — 8-K · Aug 18, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on August 18, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
• Aptose Biosciences Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: medium
  Aptose Biosciences Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
• Aptose's Cash Dries Up, Nasdaq Delisting Confirmed Amid Mounting Losses — 10-Q · Aug 13, 2025 Risk: high
  Aptose Biosciences Inc. reported a net loss of $7.043 million for the three months ended June 30, 2025, a slight improvement from the $7.252 million net loss in
• Aptose Biosciences Files 8-K — 8-K · Aug 6, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on August 6, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
• Aptose Biosciences Files Proxy Materials — DEFA14A · Aug 1, 2025 Risk: low
  Aptose Biosciences Inc. is filing a Definitive Additional Materials proxy statement on August 1, 2025. This filing relates to the company's proxy statement unde
• Aptose Biosciences Files 8-K — 8-K · Jul 15, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on July 15, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly know
• Aptose Biosciences Inc. Enters Material Definitive Agreement — 8-K · Jul 2, 2025 Risk: medium
  On June 24, 2025, Aptose Biosciences Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as L
• Aptose Biosciences Files 8-K — 8-K · Jul 1, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on July 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
• Aptose Biosciences Enters Material Definitive Agreement — 8-K · Jun 26, 2025 Risk: medium
  Aptose Biosciences Inc. entered into a material definitive agreement on June 20, 2025, which involves a direct financial obligation. The company, formerly known
• Aptose Biosciences Files 8-K on June 20, 2025 — 8-K · Jun 20, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on June 20, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosur
• Aptose Biosciences Inc. Announces Board and Compensation Changes — 8-K · Jun 18, 2025 Risk: medium
  Aptose Biosciences Inc. announced on June 16, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure
• Aptose Biosciences Inc. Files 8-K Report — 8-K · Jun 17, 2025 Risk: low
  On June 17, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing indicates the company's jurisdiction of incorporation is Canada and provides its busin
• Aptose Biosciences Files 8-K — 8-K · Jun 12, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on June 12, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known a
• Aptose Biosciences Files 8-K — 8-K · May 28, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on May 28, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial sta
• Aptose Biosciences Files 8-K — 8-K · May 20, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on May 20, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
• Aptose Biosciences Files 8-K — 8-K · May 14, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on May 14, 2025, reporting on financial statements and exhibits, and a Regulation FD Disclosure. The company, formerly know
• Aptose Biosciences Files 8-K on Financials — 8-K · May 8, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing also includes financial statemen
• Aptose Biosciences Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Aptose Biosciences Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first quar
• Aptose Biosciences Files 8-K — 8-K · May 5, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on May 5, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
• Aptose Biosciences DEF 14A: Executive Comp & Equity Awards — DEF 14A · Apr 28, 2025 Risk: medium
  Aptose Biosciences Inc. filed a DEF 14A on April 28, 2025, for the period ending May 27, 2025. The filing details executive compensation and equity awards for t
• Aptose Biosciences Files 8-K — 8-K · Apr 23, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on April 23, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
• Aptose Biosciences Changes Auditors — 8-K · Apr 21, 2025 Risk: low
  Aptose Biosciences Inc. announced on April 15, 2025, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP as its independ
• Aptose Biosciences Faces NASDAQ Delisting Notice — 8-K · Apr 3, 2025 Risk: high
  Aptose Biosciences Inc. filed an 8-K on April 3, 2025, reporting a notice of delisting or failure to meet continued listing standards with NASDAQ, effective Mar
• Aptose Biosciences Inc. Files 8-K — 8-K · Apr 1, 2025 Risk: low
  On April 1, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing indicates the company's primary business is in Biological Products, specifically exclu
• Aptose Biosciences Files 8-K on Financials — 8-K · Mar 28, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on March 28, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhi
• Aptose Biosciences Files 2024 10-K — 10-K · Mar 28, 2025 Risk: medium
  Aptose Biosciences Inc. filed its 2024 10-K on March 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Lorus Thera
• Aptose Biosciences Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 24, 2025 Risk: medium
  On March 18, 2025, Aptose Biosciences Inc. entered into a material definitive agreement and reported unregistered sales of equity securities. The filing also in
• Aptose Biosciences Files 8-K — 8-K · Mar 17, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on March 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
• Aptose Biosciences Files 8-K with Exhibits — 8-K · Mar 12, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on March 11, 2025, reporting financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and
• Aptose Biosciences Files 8-K on Security Holder Rights — 8-K · Feb 21, 2025 Risk: medium
  Aptose Biosciences Inc. filed an 8-K on February 21, 2025, reporting events as of February 18, 2025. The filing indicates material modifications to the rights o
• Aptose Biosciences Inc. Files 8-K Report — 8-K · Feb 20, 2025 Risk: low
  On February 20, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
• Aptose Biosciences Files 8-K — 8-K · Feb 18, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on February 18, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kno
• Aptose Biosciences Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Feb 13, 2025 Risk: medium
  Aptose Biosciences Inc. announced on February 7, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of eq
• Aptose Biosciences Files 8-K — 8-K · Feb 13, 2025 Risk: low
  On February 13, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits
• Aptose Biosciences Inc. Files 8-K — 8-K · Feb 12, 2025 Risk: low
  Aptose Biosciences Inc. filed an 8-K on February 12, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
• Aptose Biosciences Inc. Files 8-K for Material Agreement — 8-K · Feb 3, 2025 Risk: medium
  On February 3, 2025, Aptose Biosciences Inc. filed an 8-K report detailing a material definitive agreement. The company, previously known as Lorus Therapeutics

Risk Profile

Risk Assessment: Of APTOF's 48 recent filings, 3 were flagged as high-risk, 14 as medium-risk, and 31 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Aptose Biosciences INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $0
• Net Income: -$5.123M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $613K
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Industry Context

The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing, including venture capital, debt, and equity offerings, to fund operations. The competitive landscape is intense, with many companies vying for breakthroughs in drug discovery and development.

Top Tags

financials (19) · disclosure (18) · 8-K (11) · material-agreement (5) · exhibits (5) · filing (5) · financial-reporting (4) · financial-condition (4) · executive-compensation (3) · corporate-governance (3)

Key Numbers

• Cash and cash equivalents: $613K — Decreased from $6.152 million at Dec 31, 2024, indicating severe liquidity issues.
• Net loss (9 months): $17.7M — Reduced from $23.845 million in 2024, but still substantial for a company with no revenue.
• Accumulated deficit: $558.7M — Increased from $541.0 million at Dec 31, 2024, highlighting persistent unprofitability.
• Total shareholders' deficit: $19.5M — Worsened from $4.5 million at Dec 31, 2024, indicating negative equity.
• Research and development expenses (9 months): $7.87M — Decreased significantly from $15.560 million in 2024, potentially impacting drug development pace.
• General and administrative expenses (9 months): $9.43M — Increased from $8.510 million in 2024, despite R&D cuts and financial distress.
• Common shares outstanding: 2,552,429 — Increased from 2,006,028 at Dec 31, 2024, partly due to debt conversion, indicating dilution.
• Nasdaq minimum equity requirement: $2.5M — Aptose failed to meet this by March 31, 2025, leading to delisting.
• Loan payable to related party (non-current): $18.712M — Increased from $10.000 million at Dec 31, 2024, showing reliance on related party financing.
• Reverse stock split: 1-for-30 — Effected on February 26, 2025, to boost share price, but did not resolve underlying issues.
• Net loss for Q2 2025: $7.043M — Slight improvement from $7.252M in Q2 2024
• Net loss for H1 2025: $12.586M — Significant reduction from $16.892M in H1 2024
• Cash and cash equivalents as of June 30, 2025: $553K — Steep decline from $6.152M at Dec 31, 2024
• Negative working capital as of June 30, 2025: $5.729M — Current assets ($3.271M) less current liabilities ($9.000M)
• Accumulated deficit as of June 30, 2025: $553.6M — Increased from $541.0M at Dec 31, 2024

Related Companies

APTO · APTOS

Frequently Asked Questions